Literature DB >> 23598928

Itraconazole as 'bridge therapy' to anti-IgE in a patient with severe asthma with fungal sensitisation.

Stefano Pizzimenti1, Claudia Bussolino, Iuliana Badiu, Giovanni Rolla.   

Abstract

Sensitisation to fungi has been reported to play an important role in a particular phenotype of severe asthma, the so-called severe asthma with fungal sensitisation, characterised by high levels of total IgE, which may be an obstacle to anti-IgE therapy. We describe here the case of a polysensitised woman with refractory asthma, sensitised to Aspergillus fumigatus with high total IgE values (1793 kUA/l), but without the diagnostic criteria for allergic bronchopulmonary aspergillosis. Additional therapy with itraconazole leads to the decrease of total IgE to the limits recommended for proper omalizumab dosing (30-1500 kUA/l). Itraconazole, used as bridge therapy, provided us the opportunity to start anti-IgE treatment in a patient with high levels of total IgE, beyond the upper limits recommended for proper prescription of omalizumab.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23598928      PMCID: PMC3644922          DOI: 10.1136/bcr-2012-008462

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.

Authors:  María Del Carmen Vennera; Luis Pérez De Llano; Santiago Bardagí; Pilar Ausin; Carles Sanjuas; Héctor González; José A Gullón; Eva Martínez-Moragón; José A Carretero; Elisabet Vera; Juan F Medina; Francisco J Alvarez; Luis M Entrenas; Alicia Padilla; Rosa Irigaray; César Picado
Journal:  J Asthma       Date:  2012-03-23       Impact factor: 2.515

2.  Severe asthma with fungal sensitization in a child: response to itraconazole therapy.

Authors:  Alfin G Vicencio; Hiren Muzumdar; Kalliope Tsirilakis; Aaron Kessel; Kiran Nandalike; David L Goldman
Journal:  Pediatrics       Date:  2010-04-12       Impact factor: 7.124

3.  The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

4.  Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.

Authors:  Richard Kraemer; Natascha Deloséa; Pietro Ballinari; Sabina Gallati; Reto Crameri
Journal:  Am J Respir Crit Care Med       Date:  2006-09-07       Impact factor: 21.405

5.  Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study.

Authors:  David W Denning; B Ronan O'Driscoll; Georgina Powell; Fiona Chew; Graham T Atherton; Aashish Vyas; John Miles; Julie Morris; Robert M Niven
Journal:  Am J Respir Crit Care Med       Date:  2008-10-23       Impact factor: 21.405

6.  Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma.

Authors:  B R O'Driscoll; G Powell; F Chew; R M Niven; J F Miles; A Vyas; D W Denning
Journal:  Clin Exp Allergy       Date:  2009-08-18       Impact factor: 5.018

Review 7.  The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.

Authors:  Stephen Holgate; Roland Buhl; Jean Bousquet; Nicola Smith; Zoya Panahloo; Pablo Jimenez
Journal:  Respir Med       Date:  2009-04-10       Impact factor: 3.415

8.  Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey.

Authors:  Mahmoud Zureik; Catherine Neukirch; Bénédicte Leynaert; Renata Liard; Jean Bousquet; Françoise Neukirch
Journal:  BMJ       Date:  2002-08-24
  8 in total
  2 in total

Review 1.  Kids, Difficult Asthma and Fungus.

Authors:  Andrew Bush
Journal:  J Fungi (Basel)       Date:  2020-04-27

2.  Long-term effect of antifungal therapy for the treatment of severe resistant asthma: an active comparator clinical trial.

Authors:  Majid Mirsadraee; Sanaz Dehghan; Shadi Ghaffari; Niloofar Mirsadraee
Journal:  Curr Med Mycol       Date:  2019
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.